Ontology highlight
ABSTRACT: Objective
To estimate the relative risks of death, myocardial infarction, stroke, and renal failure or dysfunction between antifibrinolytics and no treatment following the suspension of aprotinin from the market in 2008 for safety reasons and its recent reintroduction in Europe and Canada.Design
Systematic review and network meta-analysis.Data sources
A Cochrane review of antifibrinolytic treatments was chosen as the starting point for this systematic review. Medline, Embase, and the Cochrane register of trials were searched with no date restrictions for observational evidence.Study selection
Propensity matched or adjusted observational studies with two or more of the interventions of interest (aprotinin, tranexamic acid, epsilon-aminocaproic acid, and no tr
SUBMITTER: Hutton B
PROVIDER: S-EPMC3438881 | biostudies-literature | 2012 Sep
REPOSITORIES: biostudies-literature